Co-delivery of RNA adjuvants and mRNA vaccines
| Reference number | |
| Coordinator | RISE Research Institutes of Sweden AB - Biovetenskap och hälsa |
| Funding from Vinnova | SEK 1 000 000 |
| Project duration | October 2024 - October 2025 |
| Status | Ongoing |
| Venture | Preparation projects for international application within health |
| Call | Towards deeper collaboration with UK and USA partners within Health and Life Science |
Purpose and goal
The long-term goal is development of next generation of carrier particles and formulations for adjuvants and RNA for more effective vaccines. The goal is also safer vaccines for a wide range of patients, incl. those with underlying health conditions that make them more vulnerable to side effects. The project aim is to strengthen the collaboration between RISE, PAI Life Sciences and HDT Bio around these formulations, to jointly seek long-term funding for development of RNA delivery systems.
Expected effects and result
Development of a new nanoparticle platform for delivering RNA adjuvants and mRNA vaccines. Nanoparticles can protect RNA molecules from degradation by nucleases in the body, thereby increasing the stability of the therapeutic. Additionally, the versatility of nanoparticles allows for the co-delivery of RNA adjuvants and mRNA vaccines within the same platform, creating a synergistic effect, where the adjuvant enhances the vaccine´s ability to stimulate a robust and durable immune response.
Planned approach and implementation
The project is divided into three work packages. WP1 Project management, coordination of the project activities, and reporting of results. WP2 Develop and analyze nanoparticle systems for RNA-based vaccines and adjuvants, screen nanoparticle systems and generate experimental data. WP3 IPR analysis and long-term funding. Identify suitable calls, build networks with the aim of establishing new and larger international consortia for long-term funding in the future.